JP2012503478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503478A5 JP2012503478A5 JP2011528171A JP2011528171A JP2012503478A5 JP 2012503478 A5 JP2012503478 A5 JP 2012503478A5 JP 2011528171 A JP2011528171 A JP 2011528171A JP 2011528171 A JP2011528171 A JP 2011528171A JP 2012503478 A5 JP2012503478 A5 JP 2012503478A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- nucleic acid
- genetically engineered
- engineered strain
- polyketide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108091008053 gene clusters Proteins 0.000 claims 2
- 229930001119 polyketide Natural products 0.000 claims 2
- 150000003881 polyketide derivatives Chemical class 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 101150013682 sfaA gene Proteins 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- ONJZYZYZIKTIEG-CFBQITSMSA-N (3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4-hydroxy-3,5,11-trimethyl-8-oxo-1-oxa-7-azaspiro[5.5]undecan-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-10,12-dihydroxy-3-[(3-hydroxyphenyl)methyl]-11-methyl-9- Chemical compound N1C(=O)[C@@H](CC)C[C@H](C)[C@]21[C@@H](C)[C@@H](O)[C@@H](C)[C@H](C[C@H](O)[C@@H](C)CC\C=C\C=C(/C)[C@H]1OC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](CC=3C=C(O)C=CC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(C)=O)[C@H](O)[C@@H](C)[C@@H](O)/C=C/C=C/C1)O2 ONJZYZYZIKTIEG-CFBQITSMSA-N 0.000 claims 1
- ONJZYZYZIKTIEG-UHFFFAOYSA-N Sanglifehrin A Natural products N1C(=O)C(CC)CC(C)C21C(C)C(O)C(C)C(CC(O)C(C)CCC=CC=C(C)C1OC(=O)C3CCCN(N3)C(=O)C(CC=3C=C(O)C=CC=3)NC(=O)C(C(C)C)NC(=O)C(CCC(C)=O)C(O)C(C)C(O)C=CC=CC1)O2 ONJZYZYZIKTIEG-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810200388 | 2008-09-24 | ||
| CN200810200388.4 | 2008-09-24 | ||
| PCT/CN2009/074178 WO2010034243A1 (en) | 2008-09-24 | 2009-09-24 | Novel gene cluster |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503478A JP2012503478A (ja) | 2012-02-09 |
| JP2012503478A5 true JP2012503478A5 (https=) | 2012-11-08 |
| JP5789190B2 JP5789190B2 (ja) | 2015-10-07 |
Family
ID=42059282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011528171A Expired - Fee Related JP5789190B2 (ja) | 2008-09-24 | 2009-09-24 | 新規の遺伝子クラスター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8962329B2 (https=) |
| EP (1) | EP2342335B1 (https=) |
| JP (1) | JP5789190B2 (https=) |
| CN (1) | CN102224242B (https=) |
| ES (1) | ES2556211T3 (https=) |
| WO (1) | WO2010034243A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| AU2011214135B2 (en) | 2010-02-09 | 2014-07-31 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| BR112013015501A2 (pt) * | 2010-12-20 | 2017-05-16 | Neurovive Pharmaceutical Ab | composto, composição farmacêutica, métodos para tratamento de infecções virais e de distúrbios inflamatórios, e, processo para produzir uma sangliferrina mutassintética |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| CN104263738A (zh) * | 2014-09-15 | 2015-01-07 | 武汉大学 | Fas ii抑制剂abx的生物合成基因簇 |
| TW201629069A (zh) | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10533016B2 (en) | 2015-01-09 | 2020-01-14 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| WO2017059207A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN106916834B (zh) * | 2015-12-24 | 2022-08-05 | 武汉合生科技有限公司 | 化合物的生物合成基因簇及其应用 |
| CA3020594A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| JP2020501519A (ja) | 2016-10-28 | 2020-01-23 | ギンゴー バイオワークス， インコーポレイテッド | 化合物の生産のための組成物および方法 |
| US20190002936A1 (en) | 2017-06-30 | 2019-01-03 | Washington University | Transgenic microorganisms and synthesis of piperazic acid, piperazic acid containing products, and derivatives thereof |
| CN109943545B (zh) * | 2019-03-29 | 2021-08-03 | 浙江大学 | 一种酰基转移酶结构域定向改造合成化合物的方法 |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| EP3822348A1 (de) * | 2019-11-12 | 2021-05-19 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Adaptersystem artifizieller nichtribosomaler peptidsynthetasen und polyketidsynthasen |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2164713T3 (es) * | 1993-09-20 | 2002-03-01 | Univ Leland Stanford Junior | Produccion recombinante de nuevos poliquetidos. |
| AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AP1029A (en) | 1996-07-05 | 2001-12-11 | Biotica Tech Limited | Erythromycins and process for their preparation. |
| US6265202B1 (en) | 1998-06-26 | 2001-07-24 | Regents Of The University Of Minnesota | DNA encoding methymycin and pikromycin |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| ATE453719T1 (de) | 2000-04-13 | 2010-01-15 | Biotica Tech Ltd | Glycosylierte hybrid-verbindungen, deren herstellung und verwendung |
| CA2492153C (en) | 2002-07-16 | 2012-05-08 | Biotica Technology Limited | Production of polyketide fkbp-ligand analogues |
| GB0230217D0 (en) | 2002-12-27 | 2003-02-05 | Biotica Tech Ltd | Borrelidin-producing polyketide synthase and its uses |
| GB0327721D0 (en) | 2003-11-28 | 2003-12-31 | Biotica Tech Ltd | Polyketides and their synthesis |
| GB0327720D0 (en) | 2003-11-28 | 2003-12-31 | Biotica Tech Ltd | Erythromycins and process for their preparation |
| US20090221598A1 (en) * | 2005-06-17 | 2009-09-03 | Kai Lin | Use of Sanglifehrin in HCV |
-
2009
- 2009-09-24 EP EP09815612.8A patent/EP2342335B1/en active Active
- 2009-09-24 CN CN200980146616.7A patent/CN102224242B/zh not_active Expired - Fee Related
- 2009-09-24 ES ES09815612.8T patent/ES2556211T3/es active Active
- 2009-09-24 WO PCT/CN2009/074178 patent/WO2010034243A1/en not_active Ceased
- 2009-09-24 US US13/119,868 patent/US8962329B2/en active Active
- 2009-09-24 JP JP2011528171A patent/JP5789190B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503478A5 (https=) | ||
| WO2013027999A3 (ko) | 열 안정성이 향상된 사이코스 에피머화 효소 변이체 및 이를 이용한 사이코스의 연속적 생산 | |
| JP2011062217A5 (https=) | ||
| WO2013032850A3 (en) | Compositions and methods for high fidelity assembly of nucleic acids | |
| GEP201606544B (en) | Excision of transgenes in genetically modified organisms | |
| JP2012095652A5 (https=) | ||
| NZ600540A (en) | Ethanol production in non-recombinant hosts | |
| MY157111A (en) | Recombinant microorganisms and methods of production thereof | |
| WO2008093847A1 (ja) | キシリトールデヒドロゲナーゼをコードするｄｎａ | |
| WO2013076144A3 (en) | Microorganism strains for the production of 2,3-butanediol | |
| WO2008126784A1 (ja) | グルタチオンおよびγ-グルタミルシステインの製造法 | |
| JP2007175057A5 (https=) | ||
| WO2010104390A3 (en) | Preparation of alpha-ketopimelic acid | |
| TW201217533A (en) | Genomics of actinoplanes utahensis | |
| MY164623A (en) | Method for producing high amount of glycolic acid by fermentation | |
| JP2009529905A5 (https=) | ||
| UA112783C2 (uk) | СПОСІБ ОДЕРЖАННЯ ЦЕЛЮЛАЗ З ВИКОРИСТАННЯМ МІЦЕЛІАЛЬНОГО ГРИБА, ПРИДАТНОГО ДЛЯ БІОРЕАКТОРА, ЩО МАЄ НИЗЬКИЙ ОБ'ЄМНИЙ КОЕФІЦІЕНТ ПЕРЕНЕСЕННЯ КИСНЮ kLa | |
| NZ595476A (en) | Plant snf1-related protein kinase gene | |
| CA2863578C (en) | Methods and compositions for increasing sialic acid production and treating sialic related disease conditions | |
| WO2013105802A3 (ko) | 자일로즈 이용능이 부여된 코리네박테리움 속 미생물 및 이를 이용한 ｌ-라이신의 생산방법 | |
| WO2013065046A8 (en) | Isolated polynucleotides and polypeptides, transgenic plants comprising same and uses thereof in improving abiotic stress tolerance, nitrogen use efficiency, biomass, vigor or yield of plants | |
| WO2013030176A3 (en) | Live attenuated influenza virus | |
| JP2013531967A5 (https=) | ||
| WO2013085361A3 (ko) | 4-하이드록시부티릭산 고생성능을 가지는 변이 미생물 및 이를 이용한 4-하이드록시부티릭산의 제조방법 | |
| WO2010127219A3 (en) | Altering enzyme balance through fermentation conditions |